Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.9.3.1 (cytochrome oxidase)
 8,822 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Near-infrared (NIR) spectroscopy is an inexpensive and noninvasive optical method to characterize biologic and physiologic systems. Measurements of oxygen saturation in various organs, cytochrome oxidase concentration, and glucose concentration in tissue are examples of NIR spectroscopy applications. This instrument also has potential for diagnostic imaging by comparing the optical properties of a given point in tissue with those of the surrounding areas, e.g., tumor localization, hematoma detection, or deep vein thrombosis detection. Currently, NIR spectroscopy is available in three modalities: time-resolved spectroscopy (TRS), continuous-wave spectroscopy (CWS), and a phase-modulation device. This paper describes a single-source phase-modulation device and a multiple-source (in- and anti-phased) device and their application to system identification. The phase and intensity information for homogeneous systems is correlated with system and instrumental parameters. Phase and intensity changes resulting from the presence of one and two absorbers are illustrated. The sensitivity of in- and anti-phased phase-modulation devices (phased arrays) is demonstrated. The use of amplitude-modulated phased array for heterogeneity detection is described.
 ...
PMID:Feasibility study of a single- and multiple-source near-infrared phase-modulation device for characterizing biologic systems. 926 37

After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma. Its mechanism of action involves activation of the immune system, antiangiogenic effects, and inhibition of cytokines. Thalidomide does not interact with the cytochrome oxidase system. It is not significantly metabolized, but it does undergo nonenzymatic hydrolysis in plasma. The resulting products are inactive. Despite the potential adverse effects of peripheral neuropathy, constipation, deep vein thrombosis, somnolence, rash, and orthostatic hypotension, thalidomide is an effective first-line agent for multiple myeloma in combination with dexamethasone or melphalan and prednisone. It has also been studied in the palliative care of patients with cytokine-based syndromes such as anorexia-cachexia syndrome. This review describes its use in oncology, hematology, and palliative care.
 ...
PMID:Palliative oncology: thalidomide. 1984 80